ChatGPT

Perplexity

Gemini

Claude

Grok

Patients with Medtronic heart devices that have Bluetooth® wireless telemetry can download this app for free and use it for remote monitoring. The app can be used to automatically send heart device in

You can access your pump data and sensor trends directly from a compatible Apple Watch. An easier and more discreet solution to help manage your diabetes, this feature is only available for the MiniMe

The Medtronic CareLink™  Mobile application allows clinicians who are authorized to use the CareLink™ Network to follow patients implanted with Medtronic cardiac devices to access the CareLink™ Networ

Now you can follow up to five people simultaneously. Right on your phone, The CareLink™ Connect app provides an easy way to view the sensor glucose levels of a person with diabetes using some Medtroni

Medtronic strives for the greatest possible reliability and quality in its medical devices through rigorous testing, meticulous manufacturing processes, and comprehensive quality management systems. The company's commitment to quality ensures that devices are safe, effective, and deliver consistent performance that physicians and patients can trust.

Quality and Reliability

With $2.7 billion invested in research and development in fiscal 2025, Medtronic prioritizes continuous innovation to develop next-generation medical technologies. The company leverages AI, machine learning, robotics, and advanced materials to create breakthrough therapies addressing unmet clinical needs.

Innovation and R&D Excellence

Medtronic is committed to embracing cultural differences to create an inclusive, equitable environment where every employee can thrive. Women represent 51% of the global workforce and hold 44% of global management positions, while ethnically diverse talent represents 40% of the U.S. workforce and holds 28% of leadership positions.

Inclusion and Diversity

Every decision and innovation at Medtronic is guided by the company's founding mission to alleviate pain, restore health, and extend life. Serving 79+ million patients in fiscal 2025 with a goal of 82 million in fiscal 2026, Medtronic remains relentlessly focused on improving patient outcomes and quality of life.

Patient-Centered Mission

Medtronic pursues excellence across all dimensions of operations from manufacturing efficiency and supply chain optimization to commercial execution and customer service. The company's operational discipline enables sustained profitable growth while investing in future innovation.

Operational Excellence

Medtronic plc is the world's largest medical device company by revenue, specializing in medical technology, services, and solutions for chronic diseases. Headquartered in Dublin, Ireland with operational headquarters in Minneapolis, Minnesota, Medtronic operates in more than 150 countries with over 90,000 employees, serving 79+ million patients annually across cardiovascular, neuroscience, medical surgical, and diabetes care.

Medtronic's MiniMed 600 insulin pumps potentially at risk of compromise

Medtronics killed the low cost ventilator

I'm calling Bullshit on Medtronic's Open Sourcing of a ventilator design

Secrets of the Medtronic MyCareLink Patient Monitor

FDA approves Medtronic's 'artificial pancreas' for diabetes

Geoff S. Martha

Chairman & Chief Executive Officer

Thierry Piéton

Executive Vice President & Chief Financial Officer

Sean Salmon

President, Cardiovascular Portfolio

Gregory Smith

Executive Vice President, Global Operations and Supply Chain

Lars Reger

Executive Vice President & Chief Technology Officer

Medtronic plc is an American-Irish medical device company. The company's legal and executive headquarters are in Ireland, while its operational headquarters are in Minneapolis, Minnesota. Medtronic rebased to Ireland following its acquisition of Irish-based Covidien in 2015. While it primarily operates in the United States, it operates in more than 150 countries and employs over 90,000 people. It develops and manufactures healthcare technologies and therapies. It is one of the biggest medical tech companies in the world and is currently the largest medical device company in the world by revenue. The company has developed several world-first technologies since its inception, including wearable and implantable pacemakers, the implantable cardioverter-defibrillator, and remote monitoring systems. They also created miniaturized devices like the world's smallest pacemaker and spinal cord stimulator.

Comprehensive portfolio of pacemakers (including the world's smallest pacemaker), implantable cardioverter defibrillators (ICDs), cardiac resynchronization therapy (CRT) devices, and insertable cardiac monitors for managing heart rhythm disorders. Medtronic is a global leader in pacing technology, building on Earl Bakken's pioneering 1957 invention of the first wearable pacemaker.

Cardiac Rhythm Management

Transcatheter aortic valve replacement (TAVR) systems including the Evolut FX+ platform, mitral valve repair devices, and other minimally invasive structural heart interventions for treating valvular heart disease. These technologies enable valve replacement and repair without open-heart surgery, reducing patient recovery time.

Structural Heart Therapies

Advanced insulin delivery systems including the MiniMed 780G with SmartGuard technology and the groundbreaking MiniMed 670G—the world's first FDA-approved hybrid closed-loop system that automates basal insulin delivery. The SmartGuard algorithm received FDA clearance as an interoperable automated glycemic controller compatible with Abbott's Instinct sensor.

MiniMed Insulin Pump Systems

Comprehensive spinal solutions including spinal fixation devices, biologics for bone fusion, interbody cages, and the Mazor X robotic-assisted surgery platform for complex spine procedures. Medtronic acquired nano-surface technology from Nanovis to accelerate bone growth on spinal implants in next-generation fusion devices.

Spinal Technologies and Biologics

BrainSense Adaptive Deep Brain Stimulation therapy for Parkinson's disease, essential tremor, dystonia, and epilepsy. The BrainSense Adaptive DBS technology, which received FDA approval in 2025 and was named a TIME Best Invention, provides personalized neurostimulation that adapts to patients' changing symptoms throughout the day.

Deep Brain Stimulation (DBS)

Modular robotic-assisted surgery platform designed for minimally invasive soft-tissue surgeries. Medtronic launched the Embrace Gynecology U.S. IDE clinical study to evaluate the Hugo system for hysterectomy procedures, with first total hysterectomy procedures completed at AHN West Penn Hospital in Pittsburgh.

Hugo Robotic-Assisted Surgery System

Comprehensive surgical solutions including energy devices for tissue sealing and cutting, electrosurgical instruments, laparoscopic equipment, and surgical staplers. These technologies enable minimally invasive procedures that reduce patient trauma, shorten hospital stays, and accelerate recovery.

Advanced Energy and Surgical Tools

Medtronic reported fiscal year 2025 worldwide revenue of $33.537 billion, a 3.6% increase year-over-year, with non-GAAP diluted EPS of $5.49, up 6% (10% constant currency). The company announced plans for its Diabetes business to become fully independent and provided fiscal 2026 guidance for approximately 5% organic revenue growth, demonstrating continued momentum.

Medtronic Reports Fiscal 2025 Results: $33.5 Billion Revenue, Plans Diabetes Separation

The U.S. Centers for Medicare & Medicaid Services finalized a National Coverage Determination (NCD) for renal denervation, extending Medicare coverage to qualifying patients for Medtronic's Symplicity Spyral RDN system to treat uncontrolled hypertension. The coverage decision unlocks significant market opportunities for this innovative therapy.

Medicare Approves National Coverage for Medtronic Renal Denervation System

Medtronic's BrainSense Adaptive Deep Brain Stimulation (aDBS), which received both CE Mark and U.S. FDA approval earlier in 2025, was named a 2025 TIME Best Inventions. The technology provides personalized, adaptive neurostimulation for patients with Parkinson's disease and other movement disorders, representing a major advancement in neuromodulation therapy.

Medtronic's BrainSense Adaptive DBS Named 2025 TIME Best Invention

Medtronic announced FDA clearance of the SmartGuard algorithm as an interoperable automated glycemic controller (iAGC), enabling integration with Abbott's Instinct continuous glucose monitor sensor for type 1 diabetes management. The company also received FDA approval of the MiniMed 780G system for use in adults 18+ with insulin-requiring type 2 diabetes.

Medtronic Receives FDA Clearance for SmartGuard as Interoperable Diabetes Controller

Medtronic launched the Embrace Gynecology U.S. IDE clinical study to evaluate the Hugo robotic-assisted surgery system for hysterectomy procedures. The first total hysterectomy procedures using the Hugo system were completed at AHN West Penn Hospital in Pittsburgh, advancing Medtronic's expansion in the surgical robotics market.

Medtronic Launches Hugo Robotic Surgery Gynecology Study

Medtronic announced it reversed its decision to spin-off or sell the Patient Monitoring and Respiratory Interventions businesses, instead combining them into a new Acute Care & Monitoring business unit. The company also announced discontinuation of its unprofitable ventilator product line, focusing resources on higher-growth, higher-margin product categories.

Medtronic Reorganizes Patient Monitoring Units, Discontinues Ventilators

Medtronic acquired nano-surface technology from Nanovis, a cutting-edge treatment that accelerates bone growth on spinal implants. The company is incorporating this innovation into its next-generation spinal fusion devices to improve patient outcomes and accelerate recovery times following spinal surgery.

Medtronic Acquires Nanovis Nano-Surface Technology for Spinal Implants

How difficult is to get a job at Boston scientific or Medtronic?

Hahaha... Medtronic is in damage control mode now

Medtronic Hiring

What the hell, Medtronic?

Medtronic?

I'm switching to Medtronic soon, how cooked am I?

Medtronic Job

Notes to myself on Medtronic (MDT)

Medtronic &amp; hiring process

Working at Medtronic

MedicalDevices

diabetes_t1

TwinCities

Medtronic780g

ValueInvesting

galway

Medtronic plc

Electromedical & Electrotherapeutic Apparatus

Earl Bakken and Palmer Hermundslie founded Medtronic on April 29, 1949, as a medical equipment repair shop in a garage in Minneapolis, Minnesota. With initial capital of $9 and first-month revenue of just $8, the company struggled initially but gradually built a reputation for quality equipment repair and custom electronic device fabrication.

Medtronic Founded in Minneapolis Garage

Following a power blackout in the Twin Cities that caused the death of an infant dependent on an external pacemaker, cardiac surgeon Dr. C. Walton Lillehei asked Earl Bakken to develop a battery-powered solution. Bakken designed and built the world's first wearable, battery-powered cardiac pacemaker in his garage in just four weeks.

First Wearable Battery-Powered Pacemaker Developed

Medtronic secured a licensing agreement with inventors Wilson Greatbatch and William Chardack for exclusive manufacturing and marketing rights to their implantable pacemaker design. The introduction of the implantable pacemaker in 1960 revolutionized heart rhythm disorder management and transformed Medtronic from a regional repair shop into a global medical device leader.

Introduction of Implantable Pacemaker Revolutionizes Cardiac Care

Medtronic surpassed $100 million in annual sales in 1975, demonstrating the commercial success of its pacemaker technology and establishing the company as a major player in the emerging medical device industry. This milestone validated the company's innovation-driven growth strategy.

Company Surpasses $100 Million in Annual Sales

Medtronic stock was listed on the New York Stock Exchange in 1977, providing public market currency for acquisitions and enabling broader investor access to the company's growth story. The NYSE listing marked Medtronic's transition from a private, founder-led company to a public corporation.

Medtronic Stock Listed on New York Stock Exchange

Medtronic completed the transformative acquisition of Covidien for $50 billion, creating one of the world's largest medical device companies with significantly expanded capabilities in surgical devices, minimally invasive technologies, and patient monitoring. The transaction established Medtronic's legal headquarters in Dublin, Ireland.

Covidien Acquisition Creates Global Medical Device Giant

Medtronic launched the MiniMed 670G, the world's first FDA-approved hybrid closed-loop insulin delivery system that automates basal insulin delivery for people with type 1 diabetes. This breakthrough technology represented a major advancement in automated diabetes management and continuous glucose monitoring integration.

MiniMed 670G Becomes First Hybrid Closed-Loop Insulin Pump

Medtronic acquired Mazor Robotics for $1.64 billion in September 2018, adding robotic-assisted surgery capabilities for complex spine and cranial procedures. The acquisition accelerated Medtronic's entry into the growing surgical robotics market and complemented the company's spinal device portfolio.

Mazor Robotics Acquisition for $1.64 Billion

Geoff S. Martha was appointed Chief Executive Officer of Medtronic in April 2020, bringing years of company experience in strategy, corporate development, and business unit leadership. Martha assumed the CEO role during the COVID-19 pandemic and has led the company's focus on accelerating innovation and operational excellence.

Geoff Martha Named CEO

In February 2024, Medtronic announced it reversed its decision to spin-off or sell the Patient Monitoring and Respiratory Interventions businesses, instead combining them into a new Acute Care & Monitoring business unit. The company also announced discontinuation of its unprofitable ventilator product line.

Patient Monitoring and Respiratory Interventions Reorganization

Medtronic reported fiscal year 2024 worldwide revenue of $32.364 billion, an increase of 3.6% as reported and 5.2% on an organic basis. The company generated free cash flow of $5.2 billion and announced a dividend increase, demonstrating continued financial strength and shareholder-friendly capital allocation.

Fiscal 2024 Results: $32.4 Billion Revenue with Dividend Increase

Medtronic received FDA approval for the Affera mapping and ablation system with Sphere-9 catheter for atrial fibrillation treatment and FDA clearance of the SmartGuard algorithm as an interoperable automated glycemic controller enabling integration with Abbott's Instinct sensor for type 1 diabetes management.

FDA Approvals for Affera System and SmartGuard Algorithm

Medtronic's BrainSense Adaptive Deep Brain Stimulation (aDBS) received both CE Mark and U.S. FDA approval earlier in 2025 and was named a 2025 TIME Best Inventions. The technology provides personalized, adaptive neurostimulation for patients with Parkinson's disease and other movement disorders.

BrainSense Adaptive DBS Receives FDA Approval and TIME Recognition

Medtronic reported fiscal year 2025 worldwide revenue of $33.537 billion, up 3.6% year-over-year, with non-GAAP diluted EPS of $5.49, up 6% (10% on constant currency basis). The company announced plans for the Diabetes business to become fully independent and provided fiscal 2026 guidance for approximately 5% organic revenue growth.

Fiscal 2025 Results: $33.5 Billion Revenue; Diabetes Separation Announced

The U.S. Centers for Medicare & Medicaid Services finalized a National Coverage Determination (NCD) for renal denervation on October 28, 2025, extending Medicare coverage to qualifying patients for Medtronic's Symplicity Spyral RDN system to treat uncontrolled hypertension, unlocking significant market opportunities.

Medtronic vs Oura

Medtronic

About

Oura

About

Also Compare

Track AI Visibility in Real Time